Treatment of cancer using chimeric CD3 receptor proteins
US11667691B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 5, 2016 |
| Grant date | Jun 6, 2023 |
| Priority date | — |
| Expiry date | Mar 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/70
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present disclosure features the use of chimeric CD3 proteins to modulate T cell Receptor (TCR) signaling. Specifically, the disclosure is based, in part, on the discovery that chimeric CD3 proteins (e.g., CD3delta, CD3gamma, and CD3epsilon) having all or most of their extracellular domain fused to an antigen binding domain can activate the TCR in the presence of a cognate antigen. The disclosure is further based on the observation that the above chimeric proteins can be potentiated through the inclusion of a co-stimulatory domain in the intracellular portion of the chimeric molecule. Thus, the preferred elements of the engineered signaling complexes of the disclosure include an antigen binding domain, an extracellular domain derived from one of the above CD3 proteins, and an intracellular co-stimulatory domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.